Colorectal Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Colon Cancer (141)

Rectal Cancer (64)

Colorectal Adenocarcinoma (8)

Colon Cancer (141)

Rectal Cancer (64)

Colorectal Adenocarcinoma (8)

›

HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: B - Late Trials Seagen Press Release - 2 weeks (New B) trastuzumab + tucatinib Sensitive : B Seagen Press Release - 2wk	trastuzumab + tucatinib Sensitive: B - Late Trials Seagen Press Release - 2 weeks trastuzumab + tucatinib Sensitive : B Seagen Press Release - 2 weeks - (New B)
ARID1A mutation	Colorectal Cancer	ARID1A mutation	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials Nat Commun - 2 weeks (New C3) cetuximab Resistant : C3 Nat Commun - 2wk	cetuximab Resistant: C3 – Early Trials Nat Commun - 2 weeks cetuximab Resistant : C3 Nat Commun - 2 weeks - (New C3)
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks (New C3) FORE-8394 Sensitive : C3 ESMO 2022 - 4wk	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks FORE-8394 Sensitive : C3 ESMO 2022 - 4 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab + MRTX849 Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks (New C3) cetuximab + MRTX849 Sensitive : C3 ESMO 2022 - 4wk	cetuximab + MRTX849 Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks cetuximab + MRTX849 Sensitive : C3 ESMO 2022 - 4 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	panitumumab + sotorasib Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks (New C3) panitumumab + sotorasib Sensitive : C3 ESMO 2022 - 4wk	panitumumab + sotorasib Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks panitumumab + sotorasib Sensitive : C3 ESMO 2022 - 4 weeks - (New C3)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks (New C3) bevacizumab + PCM-075 Sensitive : C3 ESMO 2022 - 4wk	bevacizumab + PCM-075 Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks bevacizumab + PCM-075 Sensitive : C3 ESMO 2022 - 4 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	bevacizumab Resistant: C3 – Early Trials ESMO 2022 - 4 weeks (New C3) bevacizumab Resistant : C3 ESMO 2022 - 4wk	bevacizumab Resistant: C3 – Early Trials ESMO 2022 - 4 weeks bevacizumab Resistant : C3 ESMO 2022 - 4 weeks - (New C3)
HER-2 amplification + KRAS exon 2 wild-type	Colorectal Cancer	HER-2 amplification + KRAS exon 2 wild-type	Colorectal Cancer	trastuzumab + lapatinib Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks (New C3) trastuzumab + lapatinib Sensitive : C3 ESMO 2022 - 4wk	trastuzumab + lapatinib Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks trastuzumab + lapatinib Sensitive : C3 ESMO 2022 - 4 weeks - (New C3)
RAS wild-type + BRAF wild-type	Colorectal Cancer	RAS wild-type + BRAF wild-type	Colorectal Cancer	nivolumab + ipilimumab + regorafenib Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks (New C3) nivolumab + ipilimumab + regorafenib Sensitive : C3 ESMO 2022 - 4wk	nivolumab + ipilimumab + regorafenib Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks nivolumab + ipilimumab + regorafenib Sensitive : C3 ESMO 2022 - 4 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	trastuzumab + tucatinib Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks (New C3) trastuzumab + tucatinib Sensitive : C3 ESMO 2022 - 4wk	trastuzumab + tucatinib Sensitive: C3 – Early Trials ESMO 2022 - 4 weeks trastuzumab + tucatinib Sensitive : C3 ESMO 2022 - 4 weeks - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	bevacizumab-bvzr Resistant: A1 - Approval bevacizumab-bvzr Resistant : A1	bevacizumab-bvzr Resistant: A1 - Approval bevacizumab-bvzr Resistant : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	ziv-aflibercept IV Sensitive: A1 - Approval ziv-aflibercept IV Sensitive : A1	ziv-aflibercept IV Sensitive: A1 - Approval ziv-aflibercept IV Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
EGFR expression	Colorectal Cancer	EGFR expression	Colorectal Cancer	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
KRAS Q61	Colorectal Cancer	KRAS Q61	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
KRAS A146	Colorectal Cancer	KRAS A146	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
KRAS K117	Colorectal Cancer	KRAS K117	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS A59	Colorectal Cancer	KRAS A59	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS G12S	Colorectal Cancer	KRAS G12S	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS G13	Colorectal Cancer	NRAS G13	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS G13	Colorectal Cancer	NRAS G13	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1

Colorectal Cancer

Associations(1152)

Associations
(1152)